Pharvaris Provides Business Update and Reports Q3 2022 Financial Results

(24/7 MARKET NEWS) – Pharvaris (Nasdaq:PHVS) announced, this morning, positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacks, and CHAPTER-1, a global proof-of-concept Phase 2 study of PHVS416, anticipated 2H2023.

The clinical-stage company also reported cash and cash equivalents of EUR198 million as of September 30, 2022.

Pharvaris is trading at $3.47, 86 cents higher (+32.95%), on nearly 300 thousand premarket shares traded.

Its 52-week range is $1.77 to 27.50. Its next inflection points are $3.49, $3.65 and $4.01.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.